Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Takeshi
Arashiro
;
Yuzo
Arima
;
Jin
Kuramochi
;
Hirokazu
Muraoka
;
Akihiro
Sato
;
Kumi
Chubachi
;
Atsushi
Yanai
;
Hiroko
Arioka
;
Yuki
Uehara
;
Genei
Ihara
;
+22 more...
Yasuyuki
Kato
;
Naoki
Yanagisawa
;
Akihiro
Ueda
;
Hideaki
Kato
;
Hideaki
Oka
;
Yusuke
Nishida
;
Yuki
Nidaira
;
Takahiro
Asami
;
Torahiko
Jinta
;
Akira
Nakamura
;
Kunihiro
Oba
;
Daisuke
Taniyama
;
Kei
Yamamoto
;
Katsushi
Tanaka
;
Kankuro
Ueshima
;
Tetsuji
Fuwa
;
Ashley
Stucky
;
Tadaki
Suzuki
;
Chris
Smith
;
Martin
Hibberd
;
Koya
Ariyoshi
;
Motoi
Suzuki
;
(2023)
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Open forum infectious diseases, 10 (6).
ofad240-.
ISSN 2328-8957
DOI: 10.1093/ofid/ofad240
;
Yuzo
Arima
;
Jin
Kuramochi
;
Hirokazu
Muraoka
;
Akihiro
Sato
;
Kumi
Chubachi
;
Atsushi
Yanai
;
Hiroko
Arioka
;
Yuki
Uehara
;
Genei
Ihara
;
+22 more...
Yasuyuki
Kato
;
Naoki
Yanagisawa
;
Akihiro
Ueda
;
Hideaki
Kato
;
Hideaki
Oka
;
Yusuke
Nishida
;
Yuki
Nidaira
;
Takahiro
Asami
;
Torahiko
Jinta
;
Akira
Nakamura
;
Kunihiro
Oba
;
Daisuke
Taniyama
;
Kei
Yamamoto
;
Katsushi
Tanaka
;
Kankuro
Ueshima
;
Tetsuji
Fuwa
;
Ashley
Stucky
;
Tadaki
Suzuki
;
Chris
Smith
;
Martin
Hibberd
;
Koya
Ariyoshi
;
Motoi
Suzuki
;
(2023)
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Open forum infectious diseases, 10 (6).
ofad240-.
ISSN 2328-8957
DOI: 10.1093/ofid/ofad240
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
-
picture_as_pdf - Arashiro-etal-2023-effectiveness-of-BA1.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
Downloads